Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
Status:
NOT_YET_RECRUITING
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This clinical trial aims to investigate the effectiveness and safety of a new treatment combination-Iparomlimab and Tuvonralimab (QL1706, a dual-function antibody targeting PD-1 and CTLA-4) combined with chemotherapy-for patients with malignant mesothelioma (MM). MM is a rare and aggressive cancer often linked to asbestos exposure. Current treatments have limited success, and this study seeks to explore a potentially more effective and safer option.
Study Design:
Phase Ib (Safety Phase): 6 patients will receive the combination therapy to assess safety. If no major safety issues arise, the study will proceed to Phase II.
Phase II (Efficacy Phase): 49 patients will be enrolled to evaluate treatment effectiveness. The study includes two groups for first-line treatment and second-line treatment.
Phase:
PHASE1
Details
Lead Sponsor:
National Cancer Center, China
Collaborators:
Affiliated Cancer Hospital of Zhengzhou University Beijing Chest Hospital, Capital Medical University Qilu Pharmaceutical Co., Ltd. Shaanxi Provincial Cancer Hospital The Affiliated Hospital of Inner Mongolia Medical University